1Lichtenstern C,Schmidt J, Knaebel HP, et al. Postoperative bacterial/fungal infections:a challenging problem in critically ill patients after abdominal surgery [J]. Dig Surg, 2007,24(1):1-11.
3Joseph S,Solomkin, John E, et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections [J]. CID ,2003,37(10):997-1005.
4Yellin AE, Heseltine PN, Berne TV, et al. The role of Pseudo-monas species in patients treated with ampicillin and sulbactam for gangrenous and perforated appendicitis[J]. Surg Gynecol Obstet, 1985,161(2):303-307.
5Malangoni MA, Condon RE, Spiegel CA. Treatment of intra-ab-dominal infections is appropriate with single-agent or combination antibiotic therapy[J]. Surgery, 1985,98(4):648.
6Chatterjee I, Iredell JR, Woods M, et al. The implications of enterococci for the intensive care unit [J]. Crit Care Resusc ,2007,9(1):69-75.
7Blot S, De Waele JJ. Critical issues in the clinical management of complicated intra-abdominal infections [J]. Drugs, 2005,65(12):1611-1620.
8Eagye KJ, Kuti JL, Dowzicky M, et al. Empiric therapy for secondary peritonitis : a pharmacodynamic analysis of cefepime, cefta-zidime, ceftriaxone, imipenem, levofloxacin, piperacillin/tazobac-tam, and tigecycline using Monte Carlo simulation[J]. Clin Ther, 2007,29(5):889-899.
9Dinubile MJ,Friedland I,Chan CY. Bowel colonization with resistant gram-negative bacilli after antimicrobial therapy of intra-abdominal infections:observations from two randomized compar-ative clinical trials of ertapenem therapyEur[J]. J Clin Microbiol Infect Dis, 2005,24(7):443- 449.
10Solomkin JS,Yellin AE, Rotstein OD, et al. Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraab-dominal infections: results of a double-blind, randomized comparative phase Ⅲ trial [J]. Ann Surg, 2003,237(2):235-245.
